Jennifer Lachey - Nov 4, 2021 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Scientific Officer
Signature
/s/ Keith Regnante, Attorney-in-Fact
Stock symbol
KROS
Transactions as of
Nov 4, 2021
Transactions value $
-$526,820
Form type
4
Date filed
11/5/2021, 05:06 PM
Previous filing
Aug 18, 2021
Next filing
Nov 12, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Options Exercise $3.18K +10.6K +12.37% $0.30* 96.3K Nov 4, 2021 Direct
transaction KROS Common Stock Sale -$530K -10.6K -11.01% $50.00 85.7K Nov 4, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -10.6K -8.17% $0.00 119K Nov 4, 2021 Common Stock 10.6K $0.30 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 Immediately exercisable.